CDC Clarivate Meta Core Meta Drugview on SAM.gov

This is a Notice of Intent, not a request for quotation. No solicitation will be issued, and no quotations will be requested. The Department of Health and Human Services, Office of Mission Acquisition Solutions (OMAS), on behalf of the Centers for Disease Control and Prevention (CDC), Agency for Toxic Substances and Disease Registry (ATSDR), Office of Innovation and Analytics (OIA), intends to award a firm-fixed-price contract to Clarivate Analytics (US) LLC for the renewal of proprietary Clarivate MetaCore and MetaDrug software licenses. The purpose of this requirement is to renew ATSDR/OIA's Clarivate MetaCore/MetaDrug software licenses for continued use by the Simulation Science Section (SSS). The RFQ identifies this requirement as a firm-fixed-price acquisition for Clarivate MetaCore and MetaDrug, Brand Name, All or None. Federal Government resellers must be authorized resellers of the required products/services. MetaCore/MetaDrug is a web-based bioinformatics suite that allows researchers to upload data analysis results from microarray, next-generation sequencing, metabolic, SAGE, siRNA, microRNA, and screening data. It provides functional analysis to identify the most relevant pathways, networks, and cellular processes in the data. Additionally, gene, protein, compound, pathway, and disease maps are available. The MetaCore/MetaDrug license includes tools for searching and data visualization, enabling identification of relevant biological pathways, networks, and processes in a virtual lab. Clarivate MetaCore/MetaDrug software will assist ATSDR/OIA/SSS and ATSDR program staff with current computational systems biology tools to help accomplish the agency's mission to investigate environmental exposures to hazardous substances in communities. With continued use, the software license will help model and understand disease pathways and build unrestricted networks of any size and data type to visualize biological relationships and molecular interactions, annotated with mechanisms, directionality, and effects. The software also supports identification and validation of targets and biomarkers and exploration of biological, chemical, and disease contexts using a comprehensive source of critical data. The requirement includes the following Clarivate software licenses: Clarivate MetaCore License Fee Clarivate MetaDrug License Fee The contemplated period of performance is August 18, 2026 through August 17, 2031, structured in annual periods as follows: Year 1: August 18, 2026 – August 17, 2027 Year 2: August 18, 2027 – August 17, 2028 Year 3: August 18, 2028 – August 17, 2029 Year 4: August 18, 2029 – August 17, 2030 Year 5: August 18, 2030 – August 17, 2031 Justification for Sole Source Clarivate Analytics (US) LLC is the proprietary provider of the required MetaCore and MetaDrug software licenses. Clarivate has certified that Clarivate Companies, including Clarivate Analytics (US) LLC, are the sole owner of MetaCore and MetaDrug and have the exclusive…